AUPH vs AZN
AUPH: Aurinia Pharmaceuticals is a biopharmaceutical company commercializing LUPKYNIS, a targeted treatment for lupus nephritis. AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline.
Side-by-side fundamentals
| Metric | AUPH | AZN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $16.74 | $168.82 | |
| Market cap | $2.2B | $254.2B | |
| P/E as of 2026-10-20 | 7.34 | n/a | |
| Net margin FY2025, SEC XBRL | n/a | +17.4% | |
| Gross margin FY2025, SEC XBRL | n/a | +81.9% | |
| Operating margin FY2025, SEC XBRL | +37.1% | +23.4% | AUPH higher |
| ROE FY2025, SEC XBRL | +49.4% | +21.0% | AUPH higher |
| ROA FY2025, SEC XBRL | +38.2% | +9.0% | AUPH higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +8.6% | |
| Revenue CAGR (3y) SEC XBRL | +28.3% | +9.8% | AUPH higher |
| Dividend yield as of 2026-09-03 | n/a | +2.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.67 | 0.34 | |
| 1-year return as of 2026-10-20 close | +41.4% | +0.6% | AUPH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.